remestemcel-L

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Grade B aGVHD

Conditions

Grade B aGVHD, Grade C aGVHD, Grade D aGVHD

Trial Timeline

Jun 4, 2015 → Apr 9, 2018

NCT ID

NCT02336230

About remestemcel-L

remestemcel-L is a phase 3 stage product being developed by Mesoblast for Grade B aGVHD. The current trial status is completed. This product is registered under clinical trial identifier NCT02336230. Target conditions include Grade B aGVHD, Grade C aGVHD, Grade D aGVHD.

What happened to similar drugs?

0 of 6 similar drugs in Grade B aGVHD were approved

Approved (0) Terminated (1) Active (5)

🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3

❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3

🔄rituximabBiogenPhase 3

🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3

🔄Remestemcel-LMesoblastPhase 3

🔄avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + AnastrozoleVerastem OncologyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04366830	Pre-clinical	Completed	—	—	Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
NCT00759018	Pre-clinical	Completed	—	—	Graft vs Host Disease
NCT02652130	Phase 3	Completed	Oct 28, 2015	Jun 15, 2018	Grade B Acute Graft Versus Host Disease
NCT02336230	Phase 3	Completed	Jun 4, 2015	Apr 9, 2018	Grade B aGVHD

Competing Products

20 competing products in Grade B aGVHD

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
azenosertib	Zentalis Pharmaceuticals	Phase 2	32
Sepantronium Bromide	Cothera Bioscience	Phase 2	29
DS-1001b	Daiichi Sankyo	Phase 2	39
Rabeprazole Sodium	Eisai	Pre-clinical	26
Binimetinib 15 MG	Ono Pharmaceutical	Phase 2	42
Abemaciclib + Letrozole	Eli Lilly	Phase 2	42
Pirtobrutinib + Mosunetuzumab	Eli Lilly	Phase 2	42
Pembrolizumab + Pemetrexed + Abemaciclib	Eli Lilly	Phase 1	21
DSP-0390	Sumitomo Pharma	Phase 1	33
Mirvetuximab soravtansine + Carboplatin	AbbVie	Phase 2	39
Mirvetuximab Soravtansine	AbbVie	Phase 2	42
Acalabrutinib + Obinutuzumab	AstraZeneca	Phase 2	42
Olaparib Pill + AZD6738	AstraZeneca	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Efineptakin alfa + Pembrolizumab	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	39
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel	Merck	Phase 2	35
Cilengitide	Merck	Phase 2	31
Avelumab	Merck	Phase 2	35